- Home
- BEAM vs NMRK Comparison
BEAM vs NMRK Comparison
Compare BEAM & NMRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- NMRK
- Stock Information
- Founded
- BEAM 2017
- NMRK 1929
- Country
- BEAM United States
- NMRK United States
- Employees
- BEAM N/A
- NMRK N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- NMRK Real Estate
- Sector
- BEAM Health Care
- NMRK Finance
- Exchange
- BEAM Nasdaq
- NMRK Nasdaq
- Market Cap
- BEAM 1.9B
- NMRK 2.2B
- IPO Year
- BEAM 2020
- NMRK 2017
- Fundamental
- Price
- BEAM $20.62
- NMRK $13.45
- Analyst Decision
- BEAM Strong Buy
- NMRK Strong Buy
- Analyst Count
- BEAM 11
- NMRK 5
- Target Price
- BEAM $48.90
- NMRK $16.25
- AVG Volume (30 Days)
- BEAM 2.6M
- NMRK 1.2M
- Earning Date
- BEAM 08-05-2025
- NMRK 07-30-2025
- Dividend Yield
- BEAM N/A
- NMRK 0.89%
- EPS Growth
- BEAM N/A
- NMRK 81.01
- EPS
- BEAM N/A
- NMRK 0.38
- Revenue
- BEAM $63,578,000.00
- NMRK $2,857,497,000.00
- Revenue This Year
- BEAM N/A
- NMRK $13.78
- Revenue Next Year
- BEAM $17.18
- NMRK $9.47
- P/E Ratio
- BEAM N/A
- NMRK $35.58
- Revenue Growth
- BEAM N/A
- NMRK 14.48
- 52 Week Low
- BEAM $13.53
- NMRK $9.65
- 52 Week High
- BEAM $35.25
- NMRK $16.10
- Technical
- Relative Strength Index (RSI)
- BEAM 55.12
- NMRK 70.59
- Support Level
- BEAM $19.40
- NMRK $12.06
- Resistance Level
- BEAM $22.76
- NMRK $13.52
- Average True Range (ATR)
- BEAM 1.32
- NMRK 0.32
- MACD
- BEAM -0.01
- NMRK 0.08
- Stochastic Oscillator
- BEAM 38.07
- NMRK 95.55
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About NMRK Newmark Group Inc.
Newmark Group Inc is a commercial real estate advisory firm. It offers services, including leasing and corporate advisory services, investment sales, commercial mortgage brokerage, appraisal and valuation, project management, and property, among others. Newmark offers a diverse array of integrated services and products designed to meet the full needs of both real estate investors/owners and occupiers. The company provides real estate strategic consulting and systems integration services to CFI's clients including many Fortune and Forbes companies, owner-occupiers, government agencies, healthcare, and higher education clients.